Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men with Late-Onset Hypogonadism

Abstract

Introduction The long-term effects of long-acting testosterone undecanoate (TU) and androgen receptor CAG repeat lengths in Thai men with late-onset hypogonadism (LOH) have not been reported. Aim To analyze the 8-year follow-up effects of intramuscular TU therapy on metabolic parameters, urinary symptoms, bone mineral density, and sexual function and investigate CAG repeat lengths in men with LOH. Methods We reviewed the medical records of 428 men with LOH who had been treated with TU and 5 patients were diagnosed with prostate cancer during TU therapy. There were 120 patients (mean age = 65.6 ± 8.9 years) who had 5 to 8 years of continuous TU supplementation and sufficiently completed records for analysis. Genomic DNA was extracted from peripheral blood and the CAG repeat region was amplified by polymerase chain reaction. Fragment analysis, sequencing, electropherography, and chromatography were performed. Main Outcome Measures The main outcome measure was dynamic parameter changes during testosterone supplementation. Results TU did not improve all obesity parameters. A statistically significant decrease was found in waist circumference, percentage of body fat, glycated hemoglobin, cholesterol, low-density lipoprotein, and International Prostate Symptom Score (P < .05). TU did not produce differences in body mass index, high-density lipoprotein, triglyceride, or the Aging Male Symptoms score from baseline. However, a statistically significant increase was found in the level of testosterone, prostate-specific antigen, hematocrit, International Index of Erectile Function score, and vertebral and femoral bone mineral density (P < .05). No major adverse cardiovascular events or prostate cancer occurred during this study. The CAG repeat length was 14 to 28 and the median CAG length was 22. There was no association between CAG repeat length and any of the anthropometric measurements. Conclusion Long-term TU treatment in men with LOH for up to 8 years appears to be safe, tolerable, and effective in correcting obesity parameters.

Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review

“…In this sense, a recent review and meta‐analysis including 16 studies and 1921 hypogonadal individuals to evaluate the efficacy and safety of testosterone therapy found that exogenous testosterone was associated with lower serum concentrations of total cholesterol only after long‐term therapy (Guo et al ., ). In turn, a study with 120 hypogonadal men showed an increase in LDL levels after 8 years of treatment (Permpongkosol et al ., ). Therefore, further long‐term clinical trials are needed to confirm the impact of androgen treatment on LDL‐cholesterol in transgender men.…”

Development of selective androgen receptor modulators (SARMs)

“…The putative beneficial effects of testosterone therapy in certain female populations appear to be outweighed by the risks of virilization and poorly characterized cardiovascular risk. Recent clinical trials, although highlighting testosterone’s ability to improve sexual function and muscle mass in older men, corroborated concerns that testosterone’s cardiac risks outweighed its therapeutic benefits (37,38). …”

Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health

“…Permpongkosol et al [135] published a 2016 observational study of testosterone treatment in 120 late-onset hypogonadal males with a mean age of 65.6 years, representing the decline in gonadal testosterone in older men. These participants were treated with intramuscular testosterone injections for 5 to 8 years, the longest study to date.…”